KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Liabilities and Shareholders Equity (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $74.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 34.35% to $74.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $299.2 million through Dec 2025, down 38.07% year-over-year, with the annual reading at $74.3 million for FY2025, 34.35% down from the prior year.
  • Liabilities and Shareholders Equity hit $74.3 million in Q4 2025 for Inovio Pharmaceuticals, up from $69.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $654.9 million in Q1 2021 to a low of $68.2 million in Q2 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $278.5 million across 5 years, with a median of $213.1 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 93.22% in 2021 and later plummeted 51.57% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $495.9 million in 2021, then decreased by 29.72% to $348.5 million in 2022, then crashed by 50.95% to $171.0 million in 2023, then crashed by 33.78% to $113.2 million in 2024, then plummeted by 34.35% to $74.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for INO at $74.3 million in Q4 2025, $69.4 million in Q3 2025, and $68.2 million in Q2 2025.